BioSpace News Archive

AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on Wednesday, November 30, 2022.

Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced the appointment of Kevin Hickey as Vice President, Brand Sales and Marketing, bolstering its executive leadership team.

Alveo Technologies, Inc. announced the appointment of three life sciences industry leaders to its senior executive team to advance the development of its novel molecular sensing and diagnostics technology and lead the company through strategic growth and commercialization of its rapid, multiplexed molecular diagnostic platform, be.well™.

The global synthetic biology market size was USD 9.26 Billion in 2021 and is expected to register a revenue CAGR of 26.3% during the forecast period.

The global gene expression market size was USD 7.17 Billion in 2020 and is expected to register a CAGR of 7.6% during the forecast period.

The global antibody-drug conjugates (ADCs) market size was significantly large in 2020, and is expected to continue to register a rapidly inclining revenue CAGR between 2021 and 2030

The global antibody production market size is expected to reach USD 37.81 Billion in 2030 and register a revenue CAGR of 14.4% during the forecast period.

Evolent Health, Inc. announced that it has entered into a definitive agreement to acquire NIA, the specialty benefit management organization owned by Centene Corporation that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine, and genetics.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”) today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).